Developments in Pharmaceutical and Biotech Patent Law 2020
Speaker(s): Benjamin C. Hsing, Daniel L. Reisner, David K. Barr, Ian Lodovice, Jennifer Gordon, Ph.D., Jonathan A. Harris, Sanjay K. Murthy Recorded on: Dec. 7, 2020
PLI Program #: 277953
View Program on PLI.edu
Ben Hsing is a partner at McGuireWoods LLP. Ben’s practice is focused on patent litigation and counseling in the life sciences industry. Ben is an accomplished trial lawyer, having tried numerous high-profile cases on behalf of major pharmaceutical and technology companies. Ben is also well versed in USPTO proceedings and assists clients in post-grant and contested patent office proceedings. In addition, Ben is experienced in conducting intellectual property due diligence investigations in connection with acquisitions and licensing deals and rendering freedom-to-operate, patentability, validity and infringement opinions. According to Chambers USA 2014, Ben is a “favorite of high-profile branded drug companies.” Chambers USA 2018 describes Ben as “a very detail-oriented attorney.” Ben is an active member of the legal community and frequently speaks on topics involving intellectual property and litigation. Ben graduated with highest honors from George Washington University Law School.
Daniel Reisner has an undergraduate degree in Physics from Wesleyan University and obtained his J.D. from New York University School of law.
He focuses on patent and trade secret litigation and intellectual property transactions. Mr. Reisner has represented large and small clients through trial in numerous matters, patent office proceedings and arbitrations involving a wide range of pharmaceutical products including Celebrex®, Viagra®, Praluent®, Gleevec®, HCV diagnostics, PocketECG arrythmia remote monitoring, Glynase® and technologies including VoIP, DOCSIS, VOD, networking, image recognition, plastic injection molding, defense and aerospace.
David K. Barr concentrates in the areas of patent, trade secret, and unfair competition litigation and counseling. Mr. Barr's experience includes litigation in federal and state courts, appeals to the Federal Circuit Court of Appeals and practice before the US Patent and Trademark Office, including contentious inter partes proceedings. Mr. Barr has been lead trial counsel in many complex Hatch-Waxman and biotech patent infringement cases, and has counseled clients on product development and strategic patent planning. He has extensive experience in intellectual property transactions, including licenses and acquisitions. Mr. Barr has also conducted numerous patent due diligence investigations, and has drafted patent license and related agreements. His patent matters have involved a variety of technologies, including biotechnology, pharmaceuticals, industrial chemistry and biomedical and mechanical devices.
Mr. Barr has authored articles and has lectured on a variety of intellectual property issues. He is a co-author and co-editor of the treatise Pharmaceutical and Biotech Patent Law (Practising Law Institute, 2016).
Mr. Barr received his law degree from the George Washington University Law School, where he was an Associate Editor of the George Washington Journal of International Law and Economics.
Ian Lodovice is currently Head of Intellectual Property at Korro, Bio. At Korro, Bio, Ian is responsible for developing and executing IP strategy to create a portfolio around Korro, Bio’s products and platform technology, to develop and execute on risk mitigation strategies related to this portfolio, and to direct IP due diligence for Korro, Bio’s business development activities. Prior to joining Korro Bio, Ian was Assistant General Counsel, IP Counsel at Biogen, Inc, and a Principal in the Life Science Practice Group at Fish & Richardson.
Jennifer Gordon is skilled in life sciences-related patent law. She has extensive experience in complex patent litigation involving biotechnology, pharmaceutical and other life sciences and chemistry-related patents. She has tried cases to judges and juries and argued appeals before the Court of Appeals for the Federal Circuit.
Dr. Gordon also has extensive experience in client counseling (including validity, infringement and freedom-to-operate analyses; strategic planning in patent procurement; as well as IP due diligence investigations related to corporate transactions). She has been involved with various patent office proceedings in the United States and abroad, including reexaminations, inter partes reviews and oppositions. She has worked with foreign counsel to coordinate and implement strategies for procuring, enforcing and defending patent rights on a worldwide basis.
Over her career, Dr. Gordon has litigated, procured and counseled on a vast array of patented technologies in the life sciences, such as nucleic acid amplification technologies (PCR), recombinant DNA technologies, cell culture methodologies, biological therapeutics (interferons, human growth hormone, monoclonal antibodies, receptor decoys, stem cells and antisense oligonucleotides), growth factors, enzymes, vaccines, genetically engineered plants, pharmaceutical compounds (cefadroxil, ezetimibe, rosiglitazone, capecitabine and valsartan), medical devices (stents) and medical diagnostics (PCR, in situ hybridization, immunoassays and NMR contrast agents).
Dr. Gordon is a member of the American Intellectual Property Law Association, The Federal Circuit Bar Association, The New York Intellectual Property Law Association, The New Jersey Intellectual Property Law Association, and The American Chemical Society. She is a frequent lecturer on numerous intellectual property topics, particularly with respect to biotechnology patent law. Ms. Gordon has been named in publications such as Chambers USA.
Jonathan Harris is a life sciences patent lawyer and partner with Axinn Veltrop. Over his 20 years of practice, he’s litigated dozens of Paragraph IV patent cases, overseen numerous IP diligence projects and prosecuted patents. As a joint JD/MBA, he has a special interest in IP due diligence.
Sanjay K. Murthy is a partner in the Intellectual Property practice in the Chicago office of Morgan Lewis and a nationally recognized trial attorney with over 20 years of experience representing life science and technology companies in US District Courts, before the Patent Trial and Appeal Board, and in Section 337 investigations in the US International Trade Commission (ITC). He has been identified as a leading practitioner by IAM Patent 1000, The Legal 500 and as a “Patent Star” by Managing Intellectual Property. He has also been recognized by The American Lawyer and Crain’s Chicago Business for his victories.
Sanjay has worked on a wide array of life science related technologies, such as pharmaceuticals, methods for manufacturing recombinant proteins, CAR-T and stem cells, and medical devices. He has represented a number of leading pharmaceutical and medical device companies, such as Takeda/Shire, GSK, Boehringer Ingelheim, and Baxter, among others.
Sanjay received an LLM in intellectual property law from The George Washington University Law School, a J.D. from California Western School of Law, where he was a dean’s full-tuition scholarship recipient, and a B.S., Biology with a minor in Chemistry from Loyola University.